Decreased platelet reactivity in patients with cancer is associated with high risk of venous thromboembolism and poor prognosis.

ABSTRACT: Platelets are suggested to play a crucial role in cancer progression and the prothrombotic state of cancer patients. Here, we aimed to examine the activation status of platelets in cancer patients and investigate their association with risk of death and occurrence of venous thromboembolism (VTE) in a prospective observational cohort study. We measured platelet surface P-selectin, activated glycoprotein (GP) IIb/IIIa and monocyte-platelet aggregate (MPA) formation in vivo and platelet response to ex vivo stimulation with agonists of protease-activated receptor (PAR) -1, -4, and GPVI, by whole blood flow cytometry, before beginning of chemotherapy and repeatedly during the first six months thereafter (total number of samples analysed: 230). Endpoints of the study were occurrence of death or

SUBMITTER: Riedl J 

PROVIDER: S-EPMC6522348 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature